nach oben

Rheumatology International

Erschienen in:

01.04.2006 | Review Article

Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review

verfasst von: Elisa Tinazzi, Vincenzo Ficarra, Sara Simeoni, Walter Artibani, Claudio Lunardi

Erschienen in: Rheumatology International | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Intravesical instillation of Bacillus Calmette-Guerin (BCG) is used with efficacy and safety in the treatment of patients with intermediate and high-risk superficial bladder carcinoma. Arthralgia and/or arthritis is one of the rare severe complications following intravesical BCG immunotherapy. We searched MEDLINE in order to analyze the frequency of this clinical complication, its pathogenesis and outcome. The electronic search was conducted using the following key words: “BCG immunotherapy” and “Arthritis, arthralgias and BCG immunotherapy”. At the end of a process of abstract analysis, 48 papers were included in the systematic review. All the selected papers, except one that was a clinical review, described at least one case of arthritis after BCG therapy. The BCG immunotherapy resulted to be safe and efficacious in the treatment of bladder cancer; the development of reactive arthritis is rare and can evolve in a chronic process. The review of the literature highlighted that reactive arthritis following BCG intravesical instillation is a complication usually well controlled with the discontinuation of the immunotherapy and nonsteroidal anti-inflammatory drugs (NSAIDs) treatment. Only a small portion of patients with a particular genetic background will develop a chronic process.

Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics 2004. Cancer J Clin 54:8–29PubMed

Messing EM, Catalona W (1998) Urothelial tumors of the urinary tract. Campbell’s urology, 7th edn. WB Saunders Co, Philadelphia

Dalbaghi G, Herr HW (2000) Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 27:137–146CrossRefPubMed

Herr HW (2000) Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year out-come. J Urol 163:60–62CrossRefPubMed

Herr HW, Schwalb DM, Zhang ZF et al (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13:1404–1416PubMed

Nseyo UO, Lamm DL (1996) Therapy of the superficial bladder cancer. Semin Oncol 23:598–604PubMed

Cheng CW, Chan SFP, Chan LW, Chan CK, Ng CF, Cheung HY et al (2004) 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach. Jpn J Clin Oncol 34 (4):202–205CrossRefPubMed

Morales A, Nickel JG (1976) Immunotherapy of superficial bladder cancer with BCG. World J Urol 3:209–214CrossRef

Lamm DL (2000) Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 31 (Suppl 3):S86–S90CrossRefPubMed

10.

Talic RF, Hargreave TB, Bishop MC, Kirk D, Prescott S (1994) Intravesical Evans bacille Calmette-Guerin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group. Br J Urol 73:645–648PubMedCrossRef

11.

Morales A, Ottenhof P, Emerson L (1981) Treatment of residual non infiltrating bladder cancer with Bacillus Calmette-Guerin. J Urol 125:649–651PubMed

12.

Lamm DL, Blumenstein BA, Crawford ED et al (1991) A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med 325:1205–1209PubMedCrossRef

13.

Hurle R, Losa A, Manzetti A, Lembo A (1999) Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7 year follow-up. Urology 54:258–263CrossRefPubMed

14.

Herr HW, Pinsky CM, Whitemore WF, Sogani PC, Oettgen HF, Melamed MR (1986) Long term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol 135:265–267PubMed

15.

Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296–1299CrossRefPubMed

16.

Satoh A, Hanawa Y, Nakamura S (2004) Clinical study of bladder cancer: proteinuria as a predictor of recurrence and efficacy of intravesical bacille Calmette-Guerin therapy. Int J Urol 11:476–482CrossRefPubMed

17.

Lamm DL, Van der Meijden ADPM, Morales A et al (1992) Incidence and treatment of Bacillus Calmette Guerain intravesical therapy in superficial bladder cancer. J Urol 147:596–600PubMed

18.

Tinazzi E, Ficarra V, Simeoni S, Peterlana D, Lunardi C (2005) Reactive arthritis following BCG immunotherapy for bladder cancer. Clin Rheumatol 24:425–427CrossRefPubMed

19.

Lamm DL, Stodgill VD, Stodgill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer. J Urol 135:272–274PubMed

20.

Hughes RA, Allard SA, Maini RN (1989) Arthritis associated with adjuvant mycobacterial treatment for carcinoma of the bladder. Ann Rheum Dis 48:432–434PubMed

21.

Ochsenkuhn T, Weber MM, Caselmann WH (1990) Arthritis after Mycobacterium bovis immunotherapy for bladder cancer. Ann Int Med 112:882PubMed

22.

al Khalifa MA, Elfving P, Mansson W, Colleen S (1991) Bacillus Calmette-Guerin treatment of 39 patients with superficial transitional cell carcinoma of the bladder. Scand J Urol Nephrol 25:135–139PubMedCrossRef

23.

Kudo S, Tsushima N, Sawadaa Y, Saito F, Motomura F, Takashima T, Kogawa T, Suzuki T, Kurotaki H, Masumori J et al (1991) Serious complications of intravesical bacillus Calmette-Guerin therapy in patients with bladder cancer. Nippon Hinyokika Gakkai Zosshi 82:1594–1602

24.

Chapman PT, Mark SD, Moller PW (1992) Arthritis associated with adjuvant mycobacterial treatment for carcinoma of the bladder. N Z Med J 105:37–38PubMed

25.

Van Thiel RJ, Nossent GD, Tjon Pian Gi NP (1992) Articular complications of intravesical BCG treatment for bladder carcinoma. Br J Urol 70:446–447PubMed

26.

Goupille P, Soutif D, Valat JP (1992) Arthritis after Calmette-Guerin bacillus immunotherapy for bladder cancer. J Rheumatol 19:1825–1826PubMed

27.

Chazerain P, Desplaces N, Ziza JM, Pierrot S, Cordonnier C, Chanzy M (1992) BCG osteoarthritis on knee prosthesis after intra-vesical BCG therapy. Rev Rhum Mal Osteoartic 59:836–838PubMed

28.

Belmatoug N, Levy-Djebbour S, Appelboom T et al (1993) Polyarthritis in 4 patients treated with intravesical BCG-therapy for carcinoma of the bladder. Rev Rhum Ed Fr 60:162–166PubMed

29.

Faus S, Martinez Montauti JM, Puig L (1993) Reiter’s syndrome after administration of intravesical bacille Calmette-Guerin. Clin Infect Dis 17:526–527PubMed

30.

Xerri B, Chretien Y, Le Parc JM (1993) Reactive polyarthritis induced by intravesical BCG therapy for carcinoma of the bladder. Eur J Med 2:503–505PubMed

31.

Jawad AS, Kahan L, Copland RF, Henderson DC, Abdul-Ahad AK (1993) Reactive arthritis associated with bacillus Calmette-Guerin immunotherapy for carcinoma of the bladder: a report of two cases. Br J Rheumatol 32:1018–1020PubMedCrossRef

32.

Pancaldi P, Van Linthoudt D, Alberino D, Haefliger JMM, Ott H (1993) Reiter’s syndrome after intravesical bacillus Calmette-Guerin treatment for superficial bladder carcinoma. Br J Rheumatol 32:1096–1098PubMedCrossRef

33.

Price GE (1994) Arthritis and iritis after BCG therapy for bladder cancer. J Rheumatol 21:564–565PubMed

34.

Goupille P, Poet JL, Jattiot F, Mattei JP, Vedere V, Tonolli-Serabian J et al (1994) Three cases of arthritis after BCG therapy for bladder cancer. Clin Exp Rheumatol 12:195–197PubMed

35.

Varoqua S, Lin-Greenberg A, Brown M (1994) Polyarthritis in an elderly man with bladder cancer. Hosp Pract 29:75–78

36.

Devlin M, Deodhar A, Davis M (1994) Arthritis as a complication of intravesical BCG vaccine. Br Med J 308:1638

37.

Thepot C, Martigny J, Simon L, Bellin J, Larget-Piet B, Chevalier X (1995) Acute polyarthritis after BCG-therapy for bladder carcinoma in a patient with ankylosing spondylitis. Rev Rhum Engl Ed 62:459–461PubMed

38.

Queiro R, Ballina J, Weruaga A, Fernandez JA, Rientra JL, Torre JC, Rodriguez A (1995) Psoriatic arthropathy after BCG immunotherapy for bladder cancer. Br J Rheumatol 34:1097PubMedCrossRef

39.

Hammadeh MY, Dutta SN, Worraall JG, Morgan RJ (1995) Acute reactive polyarthritis after intravesical bacillus Calmette-Guerin instillation. Br J Urol 76:811–812PubMed

40.

Goupille P, Valat JP (1996) Arthritis after bacillus Calmette-Guerin therapy. J Rheumatol 23:1481–1482PubMed

41.

Miossec P (1996) Reactive arthritis associated with bacillus Calmette-Guerin immunotherapy for carcinoma of the bladder: immune reactivity against mycobacterial antigens. J Rheumatol 23:1485PubMed

42.

Rodevand E, Faxvaag A, Ostensen M, Brevik B (1996) Arthritis after BCG treatment of bladder cancer. A rare complication. Tidsskr Nor Laegeforen 116:3231–3232PubMed

43.

Smith MD, Chandran G, Parker, Youssef PP, Ahern M, Coleman MA et al (1997) Synovial membrane cytokine profiles in reactive arthritis secondary to intravesical bacillus Calmette-Guerin therapy. J Rheumatol 24:752–758PubMed

44.

Saporta L, Gumus E, Karadag H, Kuran B, Miroglu C (1997) Reiter syndrome following intracavitary BCG administration. Scand J Urol Nephrol 31:211–212PubMedCrossRef

45.

Farahat MN (1997) Selective migration of the human helper/inducer T-cell subset (CD4+) in BCG-induced arthritis. Biochem Soc Trans 25:371SPubMed

46.

Hansen CP, Mortensen S (1997) Epididimo-orchitis and Reiter’s disease. Two infrequent complications after intravesical bacillus Calmette-Guerin therapy. Scand J Urol Nephrol 31:317–318PubMedCrossRef

47.

Gaston JS (1998) Role of T-cells in the development of arthritis. Clin Sci 95:19–31CrossRefPubMed

48.

Fond L, Bencharif L, Guglielminotti C, Lauwers A, Lucht F (1998) Acute oligo-arthritis in a patient treated with BCG therapy for bladder carcinoma. Presse Med 27:475PubMed

49.

Milas L, Maillefert JF, Michel F, Piroth C, Wautot A, Tavernier C (1999) Refractory arthropathy after intravesical bacillus Calmette-Guerin therapy. Usefulness of isoniazide. Rev Rhum Engl Ed 66:106–108PubMed

50.

Clavel G, Grados F, Cayrolle G, Bellony R, Leduc I, Lafont B, Ducroix JP, Fardellone P (1999) Polyarthritis following intravesical BCG immunotherapy. Report of a case and review of 26 cases in the literature. Rev Rhum Engl Ed 66:115–118PubMed

51.

Onur O, Celiker R (1999) Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Rheumatol 18:74–76CrossRefPubMed

52.

Schwartzenberg JM, Smith DD, Lindsley HB (1999) Bacillus Calmette-Guerin associated arthropathy mimicking undifferentiated spondyloarthropathy. J Rheumatol 26:933–935PubMed

53.

Chevrel G, Zech C, Miossec P (1999) Severe uveitis followed by reactive arthritis after bacillus Calmette-Guerin therapy. J Rheumatol 26:1011PubMed

54.

Varentsov GI, Zakhmatov IuM, Kornev AI, Otvetchikov IN (1999) Polyarthritis as a rare complication in BCG immunoprophylaxis of urinary bladder cancer. Urologia 5:29–30

55.

Aharon-Maor A, Shoenfeld Y (2000) The good, the bad and the ugly of vaccination. Isr Med Assoc J 2:225–227PubMed

56.

Hodish I, Ezra D, Gur H, Strego R, Olchovsky D (2000) Reiter’s syndrome after intravesical bacillus Calmette-Guerin therapy for bladder cancer. Isr Med Assoc J 2:240–241PubMed

57.

Hogarth MB, Thomas S, Seifert MH, Tariq SM (2000) Reiter’s syndrome following intravesical BCG therapy. Postgrad Med J 76:791–793CrossRefPubMed

58.

Mouly S, Berenbaum F, Kaplan G (2001) Remitting seronegative symmetrical synovitis with pitting edema following intravesical bacillus Calmette-Guerin instillation. J Rheumatol 28:1699–1701PubMed

59.

Shoenfeld Y, Aron-Maor A, Tanai A, Ehrenfeld M (2001) BCG and autoimmunity: another two-edged sword. J Autoimmun 16:235–240CrossRefPubMed

60.

Neumayr C, Kirchgatterer A, Knoflach P (2002) Chronic reactive arthritis associated with Calmette-Guerin bacillus. Dtsch Med Wochenschr 127:1886–1888CrossRefPubMed

61.

Pardalidis NP, Papatsoris AG, Kosmaoglou EV, Georganas C (2002) Two cases of acute polyarthritis secondary to intravesical BCG adjuvant therapy for superficial bladder cancer. Clin Rheumatol 21:536–537CrossRefPubMed

62.

Bartolome Pacheco MJ, Martinez-Taboada VM, Blanco R, Rodriguez-Valverde V, Valle JI, Lopez-Hoyos M (2002) Reactive arthritis after BCG immunotherapy: T cell analysis in peripheral blood and synovial fluid. Rheumatology 41: 1119–1125CrossRefPubMed

63.

Mas AJ, Romera M, Valverde-Garcia JM (2002) Articular manifestations after the administration of intravesical BCG. Joint Bone Spine 69:92–93CrossRefPubMed

64.

Pego JM, Lamas C, Hernandez I, Suso J (2003) Relapsing Reiter’s syndrome after bacillus Calmette-Guerin immunotherapy for bladder carcinoma. Med Clin 121:356–357CrossRef

65.

Shiba M, Fujii T, Takatera H (2003) Reiter syndrome after intravesical bacillus Calmette-Guerin (BCG) immunotherapy: a case report. Hinyokika Kiyo 49:599–601PubMed

66.

Narvaez J, Castro-Bohorquez FJ, Vilaseca-Momplet J (2003) Sjogren’s-like syndrome following intravesical bacillus Calmette-Guerin immunotherapy. Am J Med 115:418–419CrossRefPubMed

67.

Lam JS, Benson MC, O’Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH et al (2003) Bacillus Calmette-Guerin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21:354–360PubMed

68.

Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636–1642PubMed

69.

Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S et al (1995) Changes in urinary cytokines and solubile intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99:369–375PubMedCrossRef

70.

Luo Y, Chen X, O’Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-inbuced IFN-γ production: cytokine promotion and stimulation of BCG effect. Cytokine 21:17–26CrossRefPubMed

71.

Hara I, Nagai H, Miyake H et al (2000) Effectiveness of cancer vaccine therapy using cells transduced with the interleukine-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 7:83–90CrossRefPubMed

72.

Nagai H, Hara I, Horikawa T et al (2000) Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest 18:206–13PubMedCrossRef

73.

Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L et al (2001) T-helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 166:2142–2147CrossRefPubMed

74.

Arnold J, de Boer EC, O’Donnell MA, Bohle A, Brandau S (2004) Immunotherapy of experimental bladder cancer with recombinant BCG expressing Interferon-gamma. J Immunother 27:116–123CrossRefPubMed

75.

Yu DS, Lee CF, Hsieh DS, Chang SY (2004) Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Urology 63:596–601CrossRefPubMed

76.

Lunardi C, Bason C, Navone R et al (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6:1183–1186CrossRefPubMed

77.

Pearson CM (1964) Experimental models in rheumatoid disease. Arthritis Rheum 7:80–86PubMedCrossRef

78.

Buchs N, Chevrel G, Miossec P (1998) Bacillus Calmette-Guerin induced aseptic arthritis: an experimental model of reactive arthritis. J Rheumatol 25:1662–1665PubMed

79.

Dulphy N, Peyrat M-A, Tieng V et al (1999) Common intra-articular T cell expansions in patients with reactive arthritis: identical α-chain junctional sequences and cytotoxicity toward HLA-B27. J Immunol 162:3830–3839PubMed

80.

Shoenfeld Y, Vilner Y, Coates ARM, Rauch J, Shaul D, Pinkhas J (1986) Monoclonal antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol 66:255–261PubMed

81.

Lindqvist KJ, Coleman RE, Osterland CK (1997) Autoantibodies in chronic pulmonary tuberculosis. J Chron Dis 22:717–725CrossRef

82.

Thorns CJ, Morris JA (1985) Common epitopes between mycobacteria and certain host tissue antigens. Clin Exp Immunol 61:323–328PubMed

83.

Glynn P, Weedon D, Edwards J, Suckling AJ, Cuzner ML (1982) Humoral immunity in chronic relapsing experimental autoimmune encephalomyelitis. The major oligoclonal IgG bands are antibodies to mycobacteria. Neurol Sci 57:369–384CrossRef

84.

Van Eden W, Holoshitz J, Nevo A, Frenkel A, Klajman A, Cohen IR (1985) Arthritis induced by a T-lymphocyte clone that responds to mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci USA 82:5117–5120PubMedCrossRef

85.

Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF (1989) HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63:264–269PubMed

86.

Pockley AG (2003) Heat shock proteins as regulators of the immune response. Lancet 362:469–476CrossRefPubMed

87.

Wick G, Perschinka, Millonig G (2001) Atherosclerosis as an autoimmune disease: an update. Trends Immunol 22:665–669CrossRefPubMed

88.

Zugel U, Schoel B, Yamamoto S, Hengel H, Morein B, Kaufmann SH (1999) Crossrecognition by CD8 T cell receptor αβ cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology. Eur J Immunol 25:451–458CrossRef

89.

Hara I, Sato N, Miyake H, Muramaki M, Hikosaka S, Kamidono S (2004) Introduction of 65 kDa antigen of Mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy. Microbiol Immunol 48:289–295PubMed

90.

de Boer LC, Steerenberg PA, van der Meijen APM et al (1992) Impaired immune response by Isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol 148:1577–1582PubMed

Titel: Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review
verfasst von: Elisa Tinazzi
Vincenzo Ficarra
Sara Simeoni
Walter Artibani
Claudio Lunardi
Publikationsdatum: 01.04.2006
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 6/2006
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-005-0059-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Non-specific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders

General or personal diet: the individualized model for diet challenges in patients with rheumatoid arthritis

How do marginal osteophytes, joint space narrowing and range of motion affect each other in patients with knee osteoarthritis

Impact of pain severity and location on health-related quality of life

Familial Mediterranean fever

Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin